key: cord-0980253-bh166h1e
authors: Chavarria, Adrian Palacios; Lezama, Erika Salinas; Navarro, Mauricio Gonzalez; Vazquez, Rafael Ricardo Valdez; Bello, Héctor Herrera; Gascon, Julieta Lomelín; Juárez, Linda Morales; Avendaño, Mónica Arboleya; Gonzalez, Luis Esteban Ramirez; Ville Benavides, Rodrigo; Wyssmann, Renate Victoria Álvarez; Ortiz, Brenda Sandoval; de la Cerda, Mariana Lizbeth Rodríguez; Castañeda, Lidia Moreno; Martinez-Juarez, Luis Alberto; Gallardo-Rincón, Héctor; Tapia-Conyer, Roberto
title: High-flow nasal cannula therapy for hypoxemic respiratory failure in patients with COVID-19
date: 2021-09-03
journal: Ther Adv Infect Dis
DOI: 10.1177/20499361211042959
sha: 194f7c1039ae6dcb7b25d15b0b838a99e1d7e794
doc_id: 980253
cord_uid: bh166h1e

INTRODUCTION: High-flow nasal cannula (HFNC) therapy in patients with hypoxemic respiratory failure due to COVID-19 is poorly understood and remains controversial. METHODS: We evaluated a large cohort of patients with COVID-19-related hypoxemic respiratory failure at the temporary COVID-19 hospital in Mexico City. The primary outcome was the success rate of HFNC to prevent the progression to invasive mechanical ventilation (IMV). We also evaluated the risk factors associated with HFNC success or failure. RESULTS: HFNC use effectively prevented IMV in 71.4% of patients [270 of 378 patients; 95% confidence interval (CI) 66.6–75.8%]. Factors that were significantly different at admission included age, the presence of hypertension, and the Charlson comorbidity index. Predictors of therapy failure (adjusted hazard ratio, 95% CI) included the comorbidity-age-lymphocyte count-lactate dehydrogenase (CALL) score at admission (1.27, 1.09–1.47; p < 0.01), Rox index at 1 hour (0.82, 0.7–0.96; p = 0.02), and no prior steroid treatment (0.34, 95% CI 0.19–0.62; p < 0.0001). Patients with HFNC success rarely required admission to the intensive care unit and had shorter lengths of hospital stay [19/270 (7.0%) and 15.0 (interquartile range, 11–20) days, respectively] than those who required IMV [104/108 (96.3%) and 26.5 (20–36) days, respectively]. CONCLUSION: Treating patients with HFNC at admission led to improvement in respiratory parameters in many patients with COVID-19.

In the management of acute respiratory failure in patients with SARS-CoV-2 pneumonia, experts have agreed that following conventional oxygen therapy, the use of high-flow nasal cannula (HFNC) constitutes the next step in the therapeutic pyramid, before endotracheal intubation. 1 HFNC has emerged as an alternative, non-invasive respiratory support option that can reduce the mortality rate as well as prevent or delay the need for intubation in patients with severe acute respiratory distress caused by SARS-CoV-2 pneumonia. 2 However, despite evidence of the beneficial effect of HFNC use in patients with acute respiratory distress, 3 at present, there is limited evidence on the efficacy of HFNC in patients with severe SARS-CoV-2 pneumonia. 4 While some concerns have been raised regarding the risk of dispersion of SARS-CoV-2 through bio-aerosols, 5 the evidence to date challenges the presumption of aerosol generating procedures. 6, 7 Some concerns have also been raised regarding the risk of delayed intubation resulting in worse outcomes. 8 Based on the known usefulness of HFNC in patients with acute respiratory failure, 3 it is crucial to determine the efficacy of this non-invasive respiratory support method to avoid the need for invasive mechanical ventilation (IMV) in patients with SARS-CoV-2.

The present study, which was performed at the temporary COVID-19 hospital located in the Citibanamex Exhibition Center in Mexico City, aimed to evaluate the efficacy of HFNC in patients with hypoxemic respiratory failure due to severe SARS-CoV-2 pneumonia to reduce the risk of requiring IMV. We also aimed to identify the risk factors of disease progression among patients with severe SARS-CoV-2 pneumonia and treated with HFNC.

This prospective observational study was conducted between 16 May 2020 and 9 November 2020 in accordance with the Declaration of Helsinki. The study protocol was approved by an independent Ethical Review Board at the National Autonomous University of Mexico (FM/DI/ 099/2020). All patients provided written informed consent prior to participation.

Patients aged ⩾18 years who were admitted to the temporary COVID-19 hospital with a confirmed diagnosis of COVID-19 [as verified by a positive polymerase chain reaction (PCR) test] and hypoxemic respiratory failure (PaO 2 ⩽60 mmHg) due to severe SARS-CoV-2 pneumonia were included. For HFNC use, a respiratory rate of >24-30 breaths per minute, a PAFI ratio (PaO 2 / FiO 2 ) of 100-200, 9 and requiring a FiO 2 > 50% to achieve an oxygen saturation (SpO 2 ) of ⩾92% was necessary.

After admission, patients were initially evaluated for treatment with HFNC ( Figure 1 ). In addition, patients were also assessed for HFNC according to the Rox index (see Supplemental Figure 1 online). The Rox index is a measure of After the initial respiratory evaluation, patients who were admitted to the intermediate therapy ward and fulfilled two or more of the following criteria were admitted to the intensive care unit (ICU): (1) respiratory rate >30 rpm, (2) PAFI ratio <100, (3) lactate >1 mmol/dl, and (4) radiographic deterioration ( Figure 1 ). Patients who were admitted to the ICU were then considered for intubation according to ICU admission criteria. Among patients who initiated HFNC, admission to the ICU was based on the Rox index evaluation as follows: patients whose Rox index was <3.47 at 6 hours after initiating HFNC after a first HFNC failure, patients whose Rox index was <3.85 at 12 hours after initiating HFNC, and patients whose Rox index was <4.88 at 16 hours after initiating HFNC (see Supplemental Figure  1 online).

We evaluated demographic and clinical characteristics, duration of symptoms prior to admission, duration of HFNC or IMV, length of hospital stay, Rox index measurements, and respiratory and blood gas parameters at the start of HFNC and 16 hours after HFNC. The success of HFNC was defined as the non-progression from HFNC to IMV, with a CALL score cutoff of >6 points used to stratify the risk of progression in patients with COVID- 19. 12 Statistical methods A convenience sampling approach was used to select patients for inclusion in the study. 

The characteristics of patients included in this study are summarized in Table 1 . A total of 378 patients were included in this study and data were collected between 16 May 2020 and 9 November 2020. The median (IQR) age was 54.5 (46-64) years, and 66.7% (n = 252) were male. The proportions of patients with type 2 diabetes, hypertension, and obesity were 35.5% (n = 134), 36.8% (n = 139), and 47.6% (n = 180), respectively.

A flow chart of the outcomes of 378 patients with hypoxemic respiratory failure who were treated with HFNC is shown in Figure 2 . (Figure 3 ). The median (IQR) number of days of HFNC administration was 13 (10-18) days in patients who had success compared with 2 (1-3) days in patients who then also required IMV.

When comparing patients who required IMV and those who did not require IMV, age and the presence of hypertension were significantly different (p < 0.0001 and p = 0.03, respectively). The Charlson comorbidity index categories also differed significantly between these two groups (p < 0.0001) ( Table 1) . Patients who only Laboratory results at admission and when HFNC was commenced are summarized in Table 2 and Supplemental Table 2 online. Patients who required IMV had less favorable laboratory parameters versus those who did not require IMV. It should be noted that there were significant differences at admission and when commencing HFNC in absolute lymphocyte counts (p < 0.01 and p < 0.0001, respectively). Although markers of inflammation (median D-dimer and ferritin levels) were not significantly different between patients who only required HFNC and those who also required IMV at admission (p = 0.32 and p = 0.69, respectively), they were significantly different when commencing HFNC (p < 0.01 and p = 0.03, respectively).

Rox index values were significantly higher at each time point in patients who did not require IMV versus those who required IMV (Figure 4) (Table 3 ).

The present study is one of the largest observational prospective studies to evaluate the efficacy of HFNC use in patients with severe SARS-CoV-2 pneumonia. Our results showed that the HFNC success rate of 71.4% significantly prevented escalation to IMV in patients with hypoxemic respiratory failure due to COVID-19. This finding is important, because if HFNC was not available at our temporary COVID-19 hospital, the majority of these patients would have required IMV, which is supported in the literature across several studies. [13] [14] [15] [16] [17] CALL score at admission predicted a linear increase in the risk of IMV, with an HR of 1.27 for every point increase. The Rox index at 1 hour after starting HFNC predicted an 18% decrease in the risk of IMV for every point increase; in contrast, steroid treatment predicted a 66% decrease in the risk of IMV compared with the absence of steroid treatment.

In a multicenter prospective observational study of 293 consecutive patients with severe COVID-19-related hypoxemic respiratory failure in South Africa, the HFNC success rate (defined as the proportion of patients successfully weaned from HFNC) was 47% (137/293 patients), which is substantially lower than the 71.4% we report in the present study. 13 It was also reported that the median duration of HFNC was significantly higher in those with HFNC success versus those with HFNC failure (p < 0.001). In a study of 28 consecutive patients with hypoxemic acute respiratory failure due to SARS-CoV-2 infection in Italy, the HFNC success rate (defined as a reversal of hypoxemia or SpO 2 ⩾ 92%), was 67.8% (19/28 patients). 4 However, it was reported that only 17.8% of patients subsequently required IMV (versus 28.6% in the present study), although the small number of patients (n = 28) in that study is likely to be a confounding factor. In a larger multicenter, retrospective cohort study conducted in Wuhan, HFNC failure (defined as upgrading respiratory support to positive pressure ventilation or death) was reported in 46.5% of patients. Among these patients, 13 (30.2%) subsequently required IMV, with failure of HFNC associated with a higher mortality rate. 18 Finally, in a small study of eight patients with severe and critical COVID-19 in China, it was reported that after 2 hours of HFNC use, the Rox index was ⩾4.88 in 100% of patients and this remained above this cut-off for 12 hours. 19 It was concluded that even in severe and critical patients who were experiencing hypoxemic respiratory failure, HFNC was successful. In a previous retrospective analysis of patients with moderate-to-severe hypoxemia due to highly suspected or proven When investigating factors associated with HFNC failure, the present study found that the CALL score at admission was a significant predictor of HFNC failure. In contrast, the Rox index at 1 hour (per 1-point increase) and prior treatment with steroids were significant predictors of HFNC success. Our findings are consistent with those of a previous study, which reported that a Rox index of 6 after HFNC commencement and the use of steroids were associated with HFNC success. 13 The results of the RECOVERY trial on corticosteroid use in patients hospitalized with COVID-19 showed that early corticosteroid use (within ⩽7 days of admission) reduced mortality and ICU admissions in these patients; however, no significant difference was shown in IMV rates between early and later corticosteroid use. 21 Similar to the present study, the severity of hypoxemia and lower oxygen saturation at admission were reported to be factors associated with HFNC failure in previous studies. 4, 18 Other factors, including C reactive protein level 4 and male sex, 18 have also been previously associated with HFNC failure.

There are many potential advantages of HFNC use, including efficacy, less training needed for health-care personnel, and lower cost compared with IMV. Furthermore, in hospitals with saturated critical care capacities, the early use of HFNC is likely to have a positive effect. In contrast, some of the potential barriers of HFNC use in low resource settings include the fact that the training of health-care personnel is needed, HFNC requires the cooperation of the patient for adequate use, and, as with IMV, there are limitations in the chain of supply.

The present study has some limitations, including those inherent to the observational, single-center study design and the retrospective analysis of patients according to the management/treatment algorithms, which may have introduced bias. In addition, we did not collect data on radiological implications.

In conclusion, the present study showed that 71.4% of patients with SARS-CoV-2 pneumonia and hypoxemic respiratory failure did not require IMV when treated with HFNC; this reinforces the benefits of the timely use of HFNC. HFNC led to improvement in respiratory parameters in many patients with COVID-19 and might reduce the length of stay in the hospital and the ICU. CALL score, the Rox index at 1 hour after starting HFNC, and the presence/absence of steroid treatment were identified as predictors of HFNC outcome. These results should be validated in prospectively registered, randomized controlled trials.

Clinical consensus recommendations regarding non-invasive respiratory support in the adult patient with acute respiratory failure secondary to SARS-CoV-2 infection

Treatment for severe acute respiratory distress syndrome from COVID-19

Use of nasal high flow oxygen during acute respiratory failure

Highflow nasal cannula oxygen therapy to treat patients with hypoxemic acute respiratory failure consequent to SARS-CoV-2 infection

Respiratory support for adult patients with COVID-19

High-flow nasal cannula for COVID-19 patients: low risk of bioaerosol dispersion

Aerosol generating procedures: are they of relevance for transmission of SARS-CoV-2?

Failure of highflow nasal cannula therapy may delay intubation and increase mortality

Comparison of the SpO 2 /FIO 2 ratio and the PaO 2 /FIO 2 ratio in patients with acute lung injury or ARDS

Predicting success of high-flow nasal cannula in pneumonia patients with hypoxemic respiratory failure: the utility of the ROX index

An index combining respiratory rate and oxygenation to predict outcome of nasal high-flow therapy

Prediction for progression risk in patients with COVID-19 pneumonia: the CALL score

The utility of high-flow nasal oxygen for severe COVID-19 pneumonia in a resource-constrained setting: a multi-centre prospective observational study

High-flow nasal cannula in critically III patients with severe COVID-19

Does high-flow nasal cannula oxygen improve outcome in acute hypoxemic respiratory failure? A systematic review and meta-analysis

High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: a systematic review and meta-analysis

High-flow nasal cannula for acute hypoxemic respiratory failure in patients with COVID-19: systematic reviews of effectiveness and its risks of aerosolization, dispersion, and infection transmission

High-flow nasal oxygen in coronavirus disease 2019 patients with acute hpoxemic respiratory failure: a multicenter, retrospective cohort study

High flow nasal cannula is a good treatment option for COVID-19

Retrospective analysis of high flow nasal therapy in COVID-19-related moderate-to-severe hypoxaemic respiratory failure

Impact of corticosteroids in hospitalised COVID-19 patients

Authors' contributions APC, ESL, MGN, RRVV, HHB, MAA, LERG, RVB, RVAW, BSO, MLRC, and LMC conceived and designed the study. HGR, JLG, LMJ, LAMJ, and RTC conceived and designed the study; drafted the manuscript; acquired, analyzed, and interpreted the data; and revised the manuscript for important intellectual content. All authors read and approved of the final version to be published and agree to be accountable for all aspects of the work.

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by the Carlos Slim Foundation. We thank Michelle Belanger, MD and James Graham, PhD of Edanz Pharma, for providing medical writing support, which was funded by the Carlos Slim Foundation. Availability of supporting data Data will be made available upon reasonable request to the corresponding author.

Supplemental material for this article is available online.